Journal
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
Volume 78, Issue -, Pages 23-34Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.yjmcc.2014.11.005
Keywords
Ischemic heart disease; Myocardial infarction; Myocardial ischemia-reperfusion injury; Mitochondrial permeability transition pore; Cardioprotection
Categories
Funding
- Dorothy Hodgkin Postgraduate Award (Biotechnology and Biological Sciences Research Council)
- Department of Health's National Institute of Health Research Biomedical Research Centres
- MRC [MR/J003530/1] Funding Source: UKRI
- British Heart Foundation [FS/10/39/28270, FS/13/41/30368] Funding Source: researchfish
- Medical Research Council [MR/J003530/1] Funding Source: researchfish
Ask authors/readers for more resources
Ischemic heart disease (IHD) remains the leading cause of death and disability worldwide. For patients presenting with an acute myocardial infarction, the most effective treatment for limiting myocardial infarct (MI) size is timely reperfusion. However, in addition to the injury incurred during acute myocardial ischemia, the process of reperfusion can itself induce myocardial injury and cardiomyocyte death, termed 'myocardial reperfusion injury', the combination of which can be referred to as acute ischemia-reperfusion injury (IRI). Crucially, there is currently no effective therapy for preventing this form of injury, and novel cardioprotective therapies are therefore required to protect the heart against acute IRI in order to limit MI size and preserve cardiac function. The opening of the mitochondrial permeability transition pore (MPTP) in the first few minutes of reperfusion is known to be a critical determinant of IRI, contributing up to 50% of the final MI size. Importantly, preventing its opening at this time using MPTP inhibitors, such as cyclosporin-A, has been reported in experimental and clinical studies to reduce MI size and preserve cardiac function. However, more specific and novel MPTP inhibitors are required to translate MPTP inhibition as a cardioprotective strategy into clinical practice. In this article, we review the role of the MPTP as a mediator of acute myocardial IRI and as a therapeutic target for cardioprotection. This article is part of a Special Issue entitled Mitochondria: From Basic Mitochondrial Biology to Cardiovascular Disease. (C) 2014 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available